Unusual Increased Blood Pool Activity on 68Ga-DOTATATE PET/CT in a Patient With Metastatic Neuroendocrine Disease

Akash Sharma, Anem J. Navaz, Mukesh K. Pandey, Ephraim E. Parent

Research output: Contribution to journalArticlepeer-review

Abstract

68Ga-DOTATATE is a well-established, positron-emitting, somatostatin receptor-binding radiopharmaceutical. We present an unusual case of transiently increased blood pool uptake of 68Ga-DOTATATE in a patient with well-differentiated stage IV neuroendocrine tumor, with Ki-67 <2% (WHO grade 1) maintained on lanreotide. During serial 68Ga-DOTATATE PET/CT examinations, increased blood pool accumulation of presumably unbound 68Ga was demonstrated, which could impact the Kenning score and lead to a false treatment response assessment.

Original languageEnglish (US)
Pages (from-to)137-139
Number of pages3
JournalClinical nuclear medicine
Volume47
Issue number2
DOIs
StatePublished - Feb 1 2022

Keywords

  • Ga-DOTATATE PET/CT
  • blood pool
  • neuroendocrine tumor
  • somatostatin receptor

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Fingerprint

Dive into the research topics of 'Unusual Increased Blood Pool Activity on 68Ga-DOTATATE PET/CT in a Patient With Metastatic Neuroendocrine Disease'. Together they form a unique fingerprint.

Cite this